AACP
ARCT icon

Advantage Alpha Capital Partners’s Arcturus Therapeutics ARCT Stock Holding History

Advantage Alpha Capital Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,040
Closed -$658K – 170
2024
Q2 		$658K Sell
27,040
-2,841
-10% -$86.2K 0.14% 93
2024
Q1 		$1.01M Sell
29,881
-20,643
-41% -$731K 0.19% 102
2023
Q4 		$1.59M Buy
+50,524
New +$1.2M 0.3% 86

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advantage Alpha Capital Partners's ARCT Position: Q3 2024 in Review

Advantage Alpha Capital Partners sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 27,040 shares — an estimated $658K sold.

Advantage Alpha Capital Partners first reported a position in ARCT in Q4 2023 and held it in 3 quarters. The position peaked at $1.59M in Q4 2023. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Advantage Alpha Capital Partners reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 27,040 Arcturus Therapeutics shares in Q3 2024, an estimated $658K.
  • Advantage Alpha Capital Partners first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Arcturus Therapeutics position peaked at $1.59M in Q4 2023.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2024, filed 13 Nov 2024.